EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023)

Neil J Shah iD, Rahul Ravilla iD, Andrew J Osterland iD, Karen Todoroff iD, Ching-Yu Wang, Pratik Rane, Hakim Saal, Paul R Conkling iD, Ding Wang, Robert J Motzer iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyag326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Neil J Shah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, United States. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms, Immune Checkpoint Inhibitors. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Merck & Co., Inc., Merck Sharp & Dohme LLC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Immune checkpoint inhibitors (ICI) have become standard of care for renal cell carcinoma (RCC) in the adjuvant, first-line and pre-treated settings. However, treatment patterns and outcomes of patients with RCC that progresses following ICI treatment are not well characterized.

Methods

A retrospective review of electronic health records from a US community oncology network included patients with metastatic clear cell RCC (mccRCC) that progressed after an initial ICI-containing regimen and received subsequent systemic therapy (index) between 01/01/2018 and 01/31/2023. Patient characteristics and treatment patterns were described. Real-world progression-free survival (rwPFS) and overall survival (OS) were analyzed using Kaplan-Meier method by line of therapy (LOT) of the first ICI-containing regimen and index regimen class.

Results

Overall, 299 patients were included (median [IQR] age 68 [60-75] years, 73% male, 85% white, 87% intermediate or poor IMDC risk, median follow-up 11.3 months) with the first ICI-containing regimen initiated in the adjuvant (n = 5, 2%), first-line (n = 203, 68%) or second-line (n = 91, 30%) settings. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) monotherapy was the most common index (post-IO) regimen class (62% any VEGFR-TKI, 46% cabozantinib). Median (95% CI) rwPFS and OS were 6.0 (5.4, 6.8) and 14.3 (12.1, 16.4) months, respectively. No differences were observed in rwPFS and OS by LOT of the first ICI-containing regimen (P = 0.763, P = 0.885, respectively) or index regimen class (P = 0.721, P = 0.747, respectively).

Conclusion

In real-world patients with mccRCC that progressed to the post-ICI setting, VEGFR-TKI monotherapies were the most common post-ICI regimens and differences in clinical outcomes were not observed by LOT of the first ICI-containing regimen or index regimen class. There is high unmet need for novel therapies in the post-ICI setting.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellKidney NeoplasmsImmune Checkpoint InhibitorsHumansMaleRetrospective StudiesMiddle AgedFemaleAgedDisease Progression

Stichwörter der Autor:innen

immune checkpoint inhibitormetastaticprogression post-ICIreal-worldrenal cell carcinoma

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY 10021, United States.
  • US Oncology Network/New York Oncology Hematology, Albany, NY 12206, United States.
  • Ontada, Boston, MA 02110, United States.
  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ 07065, United States.
  • Formerly of Eisai Inc., Nutley, NJ 07110, United States.

ORCID-Profile: Neil J Shah, Rahul Ravilla, Andrew J Osterland, Karen Todoroff, Paul R Conkling, Robert J Motzer

Förderung

  • NCI NIH HHS
  • Merck & Co., Inc.
  • Merck Sharp & Dohme LLC

Zitieren

APA

Shah, N. J., Ravilla, R., Osterland, A. J., Todoroff, K., Wang, C. Y., Rane, P., Saal, H., Conkling, P. R., Wang, D., & Motzer, R. J. (2026). Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023). The Oncologist. https://doi.org/10.1093/oncolo/oyag326

Vancouver

Shah NJ, Ravilla R, Osterland AJ, Todoroff K, Wang CY, Rane P, et al. Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023). The Oncologist. 2026. doi:10.1093/oncolo/oyag326

BibTeX
@article{Shah2026,
  author = {Shah, Neil J and Ravilla, Rahul and Osterland, Andrew J and Todoroff, Karen and Wang, Ching-Yu and Rane, Pratik and Saal, Hakim and Conkling, Paul R and Wang, Ding and Motzer, Robert J},
  title = {Real-world treatment patterns and outcomes in metastatic clear cell renal cell carcinoma following immune checkpoint inhibitor progression (2018-2023)},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyag326}
}
Kostenlos starten →